| Megan Greene, PHARMD | |
|
100 Technology Center Dr, Stoughton, MA 02072-4710 | |
| (781) 566-5066 | |
| Not Available |
| Full Name | Megan Greene |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 100 Technology Center Dr, Stoughton, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053195453 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | PH234633 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Megan Greene, PHARMD 335 Sconticut Neck Rd, Fairhaven, MA 02719-1322 Ph: () - | Megan Greene, PHARMD 100 Technology Center Dr, Stoughton, MA 02072-4710 Ph: (781) 566-5066 |
News Archive
Federal officials last week OK'd allowing pharmaceutical companies to help cover patient out-of-pocket costs for costly drugs in the health law's insurance exchanges, a closely watched move by drug companies and patient advocates.
Canadian scientists have developed an innovative new technique that uses artificial intelligence to better define the different sections of the brain in newborns during a magnetic resonance imaging exam.
Research suggests that 40% of food produced in the U.S. is lost or wasted, while approximately one in eight households experiences food insecurity.
A controlled study by a group of German investigators published in the current issue of Psychotherapy and Psychosomatics indicates that brief group psychotherapy is helpful for clearing fears of disease progression (FoP) in patients with chronic arthritis or cancer. The interventions comprised either cognitive-behavioral group therapy or supportive-experiential group therapy. The investigators tested whether these generic interventions would prove effective in different illness types.
Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed headline results of the fourth and fifth of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence.
› Verified 3 days ago
Hannah Park Kim, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 100 Technology Dr, Suite 600, Stoughton, MA 02072 Phone: 516-402-7819 Fax: 617-288-5242 | |
Dr. Kimberly Marie Woumnm, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 100 Technology Center Dr Ste 600, Stoughton, MA 02072 Phone: 781-566-5370 | |
Dr. Veronica Yu, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 100 Technology Center Dr, Stoughton, MA 02072 Phone: 781-566-5066 | |
Robert David Goris-kolb, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 100 Technology Center Dr, Stoughton, MA 02072 Phone: 781-566-5066 | |
Guang Mei Fung, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 100 Technology Center Dr Ste 600, Stoughton, MA 02072 Phone: 781-566-5066 | |
Clena Deneus Rwakabuba, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 413 Washington St, Stoughton, MA 02072 Phone: 781-344-5600 Fax: 781-344-0892 |